ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.
about
General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccinationOncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in vitro and in vivo.Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer.
P2860
ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
ONCOLYTIC HERPES SIMPLEX VIRUS ...... HROUGH STRATEGIC VIRUS DESIGN.
@ast
ONCOLYTIC HERPES SIMPLEX VIRUS ...... HROUGH STRATEGIC VIRUS DESIGN.
@en
type
label
ONCOLYTIC HERPES SIMPLEX VIRUS ...... HROUGH STRATEGIC VIRUS DESIGN.
@ast
ONCOLYTIC HERPES SIMPLEX VIRUS ...... HROUGH STRATEGIC VIRUS DESIGN.
@en
prefLabel
ONCOLYTIC HERPES SIMPLEX VIRUS ...... HROUGH STRATEGIC VIRUS DESIGN.
@ast
ONCOLYTIC HERPES SIMPLEX VIRUS ...... HROUGH STRATEGIC VIRUS DESIGN.
@en
P2093
P2860
P1433
P1476
ONCOLYTIC HERPES SIMPLEX VIRUS ...... HROUGH STRATEGIC VIRUS DESIGN.
@en
P2093
P2860
P304
P356
10.1358/DOF.2010.035.03.1470166
P50
P577
2010-01-01T00:00:00Z